ZA201500129B - Anti-tumoral compositions comprising the compound 1-6(6-{[6-94-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea - Google Patents

Anti-tumoral compositions comprising the compound 1-6(6-{[6-94-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Info

Publication number
ZA201500129B
ZA201500129B ZA2015/00129A ZA201500129A ZA201500129B ZA 201500129 B ZA201500129 B ZA 201500129B ZA 2015/00129 A ZA2015/00129 A ZA 2015/00129A ZA 201500129 A ZA201500129 A ZA 201500129A ZA 201500129 B ZA201500129 B ZA 201500129B
Authority
ZA
South Africa
Prior art keywords
tumoral
ylethyl
benzothiazol
pyridazin
sulfanyl
Prior art date
Application number
ZA2015/00129A
Other languages
English (en)
Inventor
Maria-Teresa Peracchia
Amandine Mathieu
Helene Goulaouic
Tsiala Benard
Sylvie Assadourian
Jean-Rene Authelin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA201500129B publication Critical patent/ZA201500129B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
ZA2015/00129A 2012-07-12 2015-01-08 Anti-tumoral compositions comprising the compound 1-6(6-{[6-94-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea ZA201500129B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305840 2012-07-12
PCT/EP2013/064741 WO2014009500A1 (en) 2012-07-12 2013-07-11 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Publications (1)

Publication Number Publication Date
ZA201500129B true ZA201500129B (en) 2015-12-23

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/00129A ZA201500129B (en) 2012-07-12 2015-01-08 Anti-tumoral compositions comprising the compound 1-6(6-{[6-94-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Country Status (25)

Country Link
US (1) US20150119391A1 (enExample)
EP (1) EP2872119A1 (enExample)
JP (1) JP2015525754A (enExample)
KR (1) KR20150030761A (enExample)
CN (1) CN104470500A (enExample)
AR (1) AR091727A1 (enExample)
AU (1) AU2013288676A1 (enExample)
BR (1) BR112015000497A2 (enExample)
CA (1) CA2878500A1 (enExample)
CL (1) CL2015000074A1 (enExample)
CO (1) CO7160069A2 (enExample)
CR (1) CR20150005A (enExample)
EA (1) EA201590199A1 (enExample)
HK (1) HK1209642A1 (enExample)
IL (1) IL236662A0 (enExample)
IN (1) IN2015KN00075A (enExample)
MA (1) MA37753B1 (enExample)
MX (1) MX2015000532A (enExample)
PH (1) PH12015500060A1 (enExample)
SG (1) SG11201500123XA (enExample)
TN (1) TN2015000011A1 (enExample)
TW (1) TW201402121A (enExample)
UY (1) UY34909A (enExample)
WO (1) WO2014009500A1 (enExample)
ZA (1) ZA201500129B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240096905A (ko) * 2021-12-15 2024-06-26 신라젠(주) 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
EP1594434B1 (en) * 2003-01-14 2016-09-07 Yeda Research and Development Co. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
AR071354A1 (es) * 2008-02-28 2010-06-16 Takeda Pharmaceutical Composicion farmaceutica que comprende derivados de 5-(3-(etilsulfonil)fenil)-3,8-dimetil-n-(1-metilpiperidin-4-il)-9h-pirido [2,3-b]indol-7-carboxamida y una b ciclodextrina para mejorar su solubilidad
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.

Also Published As

Publication number Publication date
EP2872119A1 (en) 2015-05-20
CA2878500A1 (en) 2014-01-16
CR20150005A (es) 2015-04-06
EA201590199A1 (ru) 2015-05-29
AR091727A1 (es) 2015-02-25
UY34909A (es) 2013-11-29
BR112015000497A2 (pt) 2017-06-27
WO2014009500A1 (en) 2014-01-16
CO7160069A2 (es) 2015-01-15
MX2015000532A (es) 2015-05-15
TN2015000011A1 (en) 2016-06-29
MA37753A3 (fr) 2018-05-31
MA37753A2 (fr) 2016-06-30
TW201402121A (zh) 2014-01-16
CN104470500A (zh) 2015-03-25
SG11201500123XA (en) 2015-02-27
AU2013288676A1 (en) 2015-02-05
US20150119391A1 (en) 2015-04-30
MA37753B1 (fr) 2019-04-30
KR20150030761A (ko) 2015-03-20
IN2015KN00075A (enExample) 2015-07-31
PH12015500060A1 (en) 2015-03-02
JP2015525754A (ja) 2015-09-07
CL2015000074A1 (es) 2015-06-12
HK1209642A1 (en) 2016-04-08
IL236662A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
IL246028B (en) Compounds 2 - amino - 6 - fluoro - n - [ - fluoro - pyridine - 3 yl] pyrazolo (1, 5 - a ) pyrimidine - 3 - carboxamide, their solid forms, preparations containing them and methods for their preparation
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
EP3597649B8 (en) Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
PL2768937T3 (pl) Preparaty, ich zastosowanie jako środków do mycia naczyń lub do wytwarzania środków do mycia naczyń i ich wytwarzanie
AP3417A (en) Pyrazolo [1,5-a] pyrimidines as antiviral agents
ZA201406148B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
ME03034B (me) Jedinjenja [1 ,2 ,4]triazol0[1 ,5-c]hinazol/n-5-amina supstiтuisana sa heterobiciklo pogodna za lečenje ili prevenciju poremećaja centralnog nervnog sistema
IN2015DN03994A (enExample)
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
AP2013007147A0 (en) Use of substituted 2,3-dihydroimidazo[1,2-C]quinyzolines
SI2935274T1 (sl) 3-okso-2,3,5,8-tetrahidro-(1,2,4)triazolo(4,3-a)pirimidinski derivati za zdravljenje bolezni dihal
ZA201403441B (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid
EP2739627A4 (en) 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
IL223222A (en) Process for the preparation of 8-alkoxy [1,2,4] triazolo [c-1,5] pyrimidine-2-amine 5-converted
PL2531505T3 (pl) Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
GB2505636B (en) Extension handle for children's mechanical, wheeled vehicles
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
PT2870164T (pt) Derivados de imidazo[2,1-b]tiazol, as suas preparações e utilização como medicamentos
IL236662A0 (en) Antitumor preparation containing urea compound 1-(6-{[6-(4-fluorophenyl) [4,2,1]triazolo [3,4-b]pyridazin-3-yl]sulfanyl}-3,1-benzothiazole- 2-yl]-3-(2-morpholine-4-ylethyl)
PL2837632T3 (pl) Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
PL2531504T3 (pl) Sposób wytwarzania roztworów kompleksów metali z 3,7-diazabicyklo[3.3.1]nonanem
GB201219129D0 (en) Triazolo(4,5-d)pyrmindine compounds
AU2011903699A0 (en) An infants's wheeled vehicle